Trial Radar AI

Laten we klinische studies bespreken en verkennen waarbij Bavarian Nordic als hoofdsponsor of partner betrokken is.

Ik help u graag met vragen over gezondheidsaandoeningen, behandelingen en het vinden van klinische studies in uw buurt.
47 klinische studies
 
Type
Biologisch
×
 
Studietitel
Status
An Efficacy, Safety, and Immunogenicity Study of CHIKV VLP Vaccine for the Prevention of Chikungunya Disease in Adolescents and Adults NCT07467707
Nog niet rekruterend
Comparability Trial of the MVA-BN Vaccine Manufactured in Different Production Cells NCT07199569
Rekruterend
A Safety and Immunogenicity Study of CHIKV VLP Vaccine in Children. NCT07003984
Rekruterend
A Phase 2 Trial in Healthy Adult Participants of the Recombinant MVA-BN-WEV Vaccine NCT06899802
Actief, niet rekruterend
Phase 3 Maternal Safety & Immunogenicity Trial of MVA-BN® in DRC (PregInPoxVac) NCT06844500
Actief, niet rekruterend
Phase 3 Infant Safety & Immunogenicity Trial of MVA-BN® in DRC (PregInPoxVac) NCT06844487
Rekruterend
Long-term Follow-up Study to Evaluate Safety and Immunogenicity of PXVX0317 Single or Booster Vaccination NCT06007183
Actief, niet rekruterend
Safety and Immunogenicity of CHIKV VLP Vaccine PXVX0317 in Adults ≥65 Years NCT05349617
AfgerondResultaten gepubliceerd
ABNCoV2 Vaccine in Adult Subjects Previously Vaccinated for SARS-CoV-2 NCT05329220
AfgerondResultaten gepubliceerd
MVA-BN-RSV Vaccine Trial NCT05238025
BeëindigdResultaten gepubliceerd
ABNCoV2 Vaccine in SARS-CoV-2 (COVID-19) Seronegative and Seropositive Adult Subjects NCT05077267
AfgerondResultaten gepubliceerd
A Phase 3 Trial of the VLP-Based Chikungunya Vaccine PXVX0317 (CHIKV VLP Vaccine) NCT05072080
AfgerondResultaten gepubliceerd
A Study to Assess the Safety and Immunogenicity of PXVX0317 Chikungunya Virus Virus-Like Particle Vaccine (CHIKV VLP) NCT05065983
AfgerondResultaten gepubliceerd
Phase 2a Study of MVA-BN-RSV Vaccination and RSV Challenge in Healthy Adults NCT04752644
Afgerond
TAEK-VAC-HerBy Vaccine for Brachyury and HER2 Expressing Cancer NCT04246671
Afgerond
A Phase 1 Open Label Trial of Intravenous Administration of MVA-BN-Brachyury Vaccine in Patients With Advanced Cancer NCT04134312
Afgerond
Vaccination Trial of a Recombinant MVA-BN-WEV Vaccine in Healthy Adult Subjects NCT04131595
Afgerond
Phase 2 Open-label Study of Alum-adjuvanted Chikungunya Virus-like Particle Vaccine (PXVX0317) (WRAIR) NCT03992872
AfgerondResultaten gepubliceerd
Freeze-Dried MVA-BN® Lot Consistency Smallpox Trial NCT03699124
AfgerondResultaten gepubliceerd
CV301 Combined With PD-1/L1 Blockade in Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer NCT03628716
AfgerondResultaten gepubliceerd
Safety, Reactogenicity and Immunogenicity of Adenovirus Serotype 26 (Ad26)- and Modified Vaccinia Ankara (MVA)-Vectored Vaccine Components in Otherwise Healthy Women With HPV16 or HPV18 Infection of the Cervix NCT03610581
BeëindigdResultaten gepubliceerd
BN Brachyury and Radiation in Chordoma NCT03595228
AfgerondResultaten gepubliceerd
A Trial of Perioperative CV301 Vaccination in Combination With Nivolumab and Systemic Chemotherapy for Metastatic CRC NCT03547999
BeëindigdResultaten gepubliceerd
Neoantigen DNA Vaccine in Combination With Nivolumab/Ipilimumab and PROSTVAC in Metastatic Hormone-Sensitive Prostate Cancer NCT03532217
Afgerond
Trial of a Chikungunya Vaccine, PXVX0317 CHIKV-VLP, in Healthy Adults NCT03483961
AfgerondResultaten gepubliceerd
Special Access Program IMVAMUNE® NCT03472014
AfgerondResultaten gepubliceerd
Durvalumab Plus CV301 With Maintenance Chemotherapy in Metastatic Colorectal or Pancreatic Adenocarcinoma NCT03376659
BeëindigdResultaten gepubliceerd
Safety and Tolerability Trial (MVA-BN-Brachyury/FPV-Brachyury) NCT03349983
Afgerond
VAXCHORA Pediatric Study to Assess Safety and Immunogenicity NCT03220737
AfgerondResultaten gepubliceerd
JYNNEOS Smallpox Vaccine in Adult Healthcare Personnel at Risk for Mpox in the Democratic Republic of the Congo NCT02977715
Actief, niet rekruterend
RSV-MVA-BN Vaccine Phase II Trial in ≥ 55 Year Old Adults NCT02873286
AfgerondResultaten gepubliceerd
RSV-MVA-BN Vaccine Phase I Trial, Intranasal Application in Adults. NCT02864628
Ingetrokken
A Trial of CV301 in Combination With Anti-PD-1 Therapy in Subjects With Non-Small Cell Lung Cancer NCT02840994
Afgerond
Adjuvant PROSTVAC-V/F in Subjects at High Risk for Relapse After Radical Prostatectomy NCT02772562
BeëindigdResultaten gepubliceerd
Long-term Safety Follow-up of Participants Exposed to the Candidate Ebola Vaccines Ad26.ZEBOV and/or MVA-BN-Filo NCT02661464
BeëindigdResultaten gepubliceerd
Neoadjuvant PROSTVAC-VF With or Without Ipilimumab for Prostate Cancer NCT02506114
BeëindigdResultaten gepubliceerd
Trial to Evaluate the Safety, Tolerability and Immunogenicity of the Recombinant MVA BN® RSV Vaccine NCT02419391
Afgerond
Phase 4 Study To Assess The Safety Of Vivotif At Different Release Titers Among Travelers NCT02391909
Afgerond
A Study of Live Oral Cholera Vaccine, PXVX200 in Healthy Older Adults NCT02100631
AfgerondResultaten gepubliceerd
A Phase 3 Lot to Lot Consistency Study of Live Oral Cholera Vaccine, PXVX0200 in Healthy Adults NCT02094586
AfgerondResultaten gepubliceerd
Randomized, Open-label Phase II Trial to Assess the Safety and Immunogenicity of MVA-BN Smallpox Vaccine in Immunocompromised Subjects With HIV Infection NCT02038881
AfgerondResultaten gepubliceerd
A Non-inferiority Trial to Compare MVA-BN® Smallpox Vaccine to ACAM2000® NCT01913353
AfgerondResultaten gepubliceerd
Safety and Efficacy Challenge Study of Live Oral Cholera Vaccine Candidate,PXVX0200, to Prevent Cholera NCT01895855
AfgerondResultaten gepubliceerd
A Phase II Trial to Compare a Liquid-frozen and a Freeze-dried Formulation of IMVAMUNE (MVA-BN®) Smallpox Vaccine in Vaccinia-naïve Healthy Subjects NCT01668537
AfgerondResultaten gepubliceerd
Safety and Immunogenicity of the Live Oral Cholera Vaccine Candidate PXVX0200 NCT01585181
Afgerond
A Randomized, Double-blind, Phase 3 Efficacy Trial of PROSTVAC-V/F +/- GM-CSF in Men With Asymptomatic or Minimally Symptomatic Metastatic Castrate-Resistant Prostate Cancer (Prospect) NCT01322490
AfgerondResultaten gepubliceerd
A Safety and Immunology Study of a Modified Vaccinia Vaccine for HER-2(+) Breast Cancer After Adjuvant Therapy NCT01152398
Afgerond